Cargando…

Administration of Intravenous Furosemide in Patients with Acute Infection: Patient Characteristics and Impact on In-Hospital Outcome

Intravenous (IV) fluid is frequently used to treat patients who have been admitted with an acute infection; among these patients, some will experience pulmonary congestion and will need diuretic treatment. Consecutive admissions to the Internal Medicine Department of patients with an acute infection...

Descripción completa

Detalles Bibliográficos
Autores principales: Levi, Nir, Bnaya, Alon, Wolak, Arik, Shavit, Linda, Jaffal, Sabre, Amsalem, Itshak, Hitter, Rafael, Wolak, Talya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10218796/
https://www.ncbi.nlm.nih.gov/pubmed/37240603
http://dx.doi.org/10.3390/jcm12103496
_version_ 1785048858847346688
author Levi, Nir
Bnaya, Alon
Wolak, Arik
Shavit, Linda
Jaffal, Sabre
Amsalem, Itshak
Hitter, Rafael
Wolak, Talya
author_facet Levi, Nir
Bnaya, Alon
Wolak, Arik
Shavit, Linda
Jaffal, Sabre
Amsalem, Itshak
Hitter, Rafael
Wolak, Talya
author_sort Levi, Nir
collection PubMed
description Intravenous (IV) fluid is frequently used to treat patients who have been admitted with an acute infection; among these patients, some will experience pulmonary congestion and will need diuretic treatment. Consecutive admissions to the Internal Medicine Department of patients with an acute infection were included. Patients were divided based on IV furosemide treatment within 48 h after admission. A total of 3556 admissions were included: In 1096 (30.8%), furosemide was administered after ≥48 h, and in 2639 (74.2%), IV fluid was administered within <48 h. Mean age was 77.2 ± 15.8 years, and 1802 (50.7%) admissions were females. In a multivariable analysis, older age (OR 1.01 [95% CI, 1.00–1.01]), male gender (OR 0.74 [95% CI, 0.63–0.86]), any cardiovascular disease (OR 1.51 [95% CI, 1.23–1.85]), congestive heart failure (CHF) (OR 2.81 [95% CI, 2.33–3.39), hypertension (OR 1.42 [95% CI, 1.22–1.67]), respiratory infection (OR 1.38 [95% CI, 1.17–1.63]), and any IV fluid administration (OR 3.37 [95% CI, 2.80–4.06]) were independently associated with furosemide treatment >48 h after hospital admission. In-hospital mortality was higher in patients with furosemide treatment (15.9% vs. 6.8%, p < 0.001). Treatment with furosemide in patients admitted with an infection was found to be associated with prolonged hospital stay and increased in-hospital mortality.
format Online
Article
Text
id pubmed-10218796
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102187962023-05-27 Administration of Intravenous Furosemide in Patients with Acute Infection: Patient Characteristics and Impact on In-Hospital Outcome Levi, Nir Bnaya, Alon Wolak, Arik Shavit, Linda Jaffal, Sabre Amsalem, Itshak Hitter, Rafael Wolak, Talya J Clin Med Article Intravenous (IV) fluid is frequently used to treat patients who have been admitted with an acute infection; among these patients, some will experience pulmonary congestion and will need diuretic treatment. Consecutive admissions to the Internal Medicine Department of patients with an acute infection were included. Patients were divided based on IV furosemide treatment within 48 h after admission. A total of 3556 admissions were included: In 1096 (30.8%), furosemide was administered after ≥48 h, and in 2639 (74.2%), IV fluid was administered within <48 h. Mean age was 77.2 ± 15.8 years, and 1802 (50.7%) admissions were females. In a multivariable analysis, older age (OR 1.01 [95% CI, 1.00–1.01]), male gender (OR 0.74 [95% CI, 0.63–0.86]), any cardiovascular disease (OR 1.51 [95% CI, 1.23–1.85]), congestive heart failure (CHF) (OR 2.81 [95% CI, 2.33–3.39), hypertension (OR 1.42 [95% CI, 1.22–1.67]), respiratory infection (OR 1.38 [95% CI, 1.17–1.63]), and any IV fluid administration (OR 3.37 [95% CI, 2.80–4.06]) were independently associated with furosemide treatment >48 h after hospital admission. In-hospital mortality was higher in patients with furosemide treatment (15.9% vs. 6.8%, p < 0.001). Treatment with furosemide in patients admitted with an infection was found to be associated with prolonged hospital stay and increased in-hospital mortality. MDPI 2023-05-16 /pmc/articles/PMC10218796/ /pubmed/37240603 http://dx.doi.org/10.3390/jcm12103496 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Levi, Nir
Bnaya, Alon
Wolak, Arik
Shavit, Linda
Jaffal, Sabre
Amsalem, Itshak
Hitter, Rafael
Wolak, Talya
Administration of Intravenous Furosemide in Patients with Acute Infection: Patient Characteristics and Impact on In-Hospital Outcome
title Administration of Intravenous Furosemide in Patients with Acute Infection: Patient Characteristics and Impact on In-Hospital Outcome
title_full Administration of Intravenous Furosemide in Patients with Acute Infection: Patient Characteristics and Impact on In-Hospital Outcome
title_fullStr Administration of Intravenous Furosemide in Patients with Acute Infection: Patient Characteristics and Impact on In-Hospital Outcome
title_full_unstemmed Administration of Intravenous Furosemide in Patients with Acute Infection: Patient Characteristics and Impact on In-Hospital Outcome
title_short Administration of Intravenous Furosemide in Patients with Acute Infection: Patient Characteristics and Impact on In-Hospital Outcome
title_sort administration of intravenous furosemide in patients with acute infection: patient characteristics and impact on in-hospital outcome
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10218796/
https://www.ncbi.nlm.nih.gov/pubmed/37240603
http://dx.doi.org/10.3390/jcm12103496
work_keys_str_mv AT levinir administrationofintravenousfurosemideinpatientswithacuteinfectionpatientcharacteristicsandimpactoninhospitaloutcome
AT bnayaalon administrationofintravenousfurosemideinpatientswithacuteinfectionpatientcharacteristicsandimpactoninhospitaloutcome
AT wolakarik administrationofintravenousfurosemideinpatientswithacuteinfectionpatientcharacteristicsandimpactoninhospitaloutcome
AT shavitlinda administrationofintravenousfurosemideinpatientswithacuteinfectionpatientcharacteristicsandimpactoninhospitaloutcome
AT jaffalsabre administrationofintravenousfurosemideinpatientswithacuteinfectionpatientcharacteristicsandimpactoninhospitaloutcome
AT amsalemitshak administrationofintravenousfurosemideinpatientswithacuteinfectionpatientcharacteristicsandimpactoninhospitaloutcome
AT hitterrafael administrationofintravenousfurosemideinpatientswithacuteinfectionpatientcharacteristicsandimpactoninhospitaloutcome
AT wolaktalya administrationofintravenousfurosemideinpatientswithacuteinfectionpatientcharacteristicsandimpactoninhospitaloutcome